Full-Time

Senior Director

Quality Compliance and Risk Management

Braveheart Bio

Braveheart Bio

11-50 employees

Develops cardiac myosin inhibitors for HCM

Compensation Overview

$225k - $290k/yr

+ Annual bonus + Equity

Remote in USA + 1 more

More locations: San Francisco, CA, USA

Hybrid

The role may be performed in San Francisco or remotely; hybrid work is also listed.

Bachelor's

Category
Biology & Biotech (1)
Required Skills
GMP
Risk Management
Google Cloud Platform

Get referred to Braveheart Bio

See people who can refer or advise you

Requirements
  • A bachelor's degree in life science, quality, engineering, or a related discipline.
  • At least 15 years of progressive pharmaceutical or biotechnology quality experience.
  • Broad and substantive experience across multiple GxP disciplines, including GMP, GCP, GLP/nonclinical, data integrity, computerized systems, and other regulated activities.
  • Significant experience in quality compliance, quality risk management, inspection readiness, GxP auditing, and vendor oversight.
  • Demonstrated experience performing GxP gap analyses, compliance assessments, data integrity assessments, and risk-based evaluation and mitigation of identified gaps.
  • Significant experience hosting and managing regulatory authority inspections, including inspection preparation, front-room/back-room management, document requests, subject matter expert preparation, inspector interactions, response development, and follow-up.
  • Demonstrated experience developing, conducting, or overseeing risk-based internal and external GxP audit programs.
  • Demonstrated experience managing risk-based vendor qualification, periodic evaluation, re-evaluation, and continued oversight programs.
  • Demonstrated ability to apply quality risk management principles to complex issues, systems, vendors, data, and business decisions.
  • Strong independent quality judgment, including the ability to recognize significant or systemic risks, distinguish critical issues from lower-risk concerns, and drive appropriate action and escalation.
  • Demonstrated ability to rapidly assess unfamiliar or complex GxP issues, identify critical quality risks, engage appropriate subject matter experts, and drive risk-based decisions.
  • Excellent organizational, problem-solving, prioritization, and time-management skills, with the ability to manage multiple complex activities simultaneously.
  • Strong written and verbal communication skills with a collaborative, team-oriented approach.
  • Ability to thrive in a fast-paced, dynamic environment and remain comfortable with change and ambiguity.
  • A flexible, proactive, and hands-on mindset.
Responsibilities
  • Maintain organizational inspection readiness through ongoing GxP gap assessments, readiness reviews, mock inspections, document and process readiness activities, and tracking of significant gaps and mitigation activities.
  • Perform and coordinate data integrity assessments, compliance gap analyses, and quality risk assessments across GxP activities, including evaluation of in-licensed programs and data packages; work with subject matter experts to characterize risks and develop mitigation strategies.
  • Own the GxP vendor qualification and oversight program, including vendor risk classification, initial qualification, periodic evaluation, re-evaluation, continued qualification, ongoing compliance and performance monitoring, and maintenance of oversight documentation.
  • Develop and coordinate the risk-based external audit program and global audit calendar, including identification and coordination of qualified internal or external auditors and oversight of significant findings, responses, and corrective actions.
  • Develop and execute the internal quality audit program, including risk-based planning, execution, reporting, and follow-up.
  • Manage regulatory authority inspections, including inspection planning, front-room/back-room activities, document requests, subject matter expert preparation, inspector interactions, response development, post-inspection follow-up, and tracking of inspection commitments through closure.
  • Establish and maintain practical quality risk management approaches for significant compliance issues and ensure material or systemic risks are evaluated, documented, communicated, and escalated.
  • Provide quality oversight of significant data integrity concerns and collaborate with IT, Legal, and the Data Protection Officer on data breaches or privacy events affecting GxP systems, data, records, product quality, patient safety, or regulatory compliance.
  • Provide quality oversight of GxP computerized systems and computerized system validation activities and may assume responsibility for the computerized system validation program.
  • Monitor regulatory developments, inspection trends, enforcement activity, and evolving GxP expectations and assess implications for company quality systems and regulated activities.
  • Provide senior-level quality judgment on complex compliance and risk matters and flex across quality responsibilities as needed.
Desired Qualifications
  • Experience working in a small, rapidly growing, or startup pharmaceutical or biotechnology organization.
  • Experience supporting late-stage clinical development, regulatory submissions, and transition to commercial operations.
  • Experience evaluating in-licensed programs or data packages and developing risk-based strategies to address identified gaps.
  • Experience with computerized system validation, IT Quality, and data integrity sufficient to assume primary responsibility for the computerized system validation program, if needed.
  • Experience with regulatory intelligence and evaluation of emerging GxP compliance expectations.
  • Prior experience in a broad Quality leadership role requiring meaningful experience across multiple GxP disciplines rather than a single specialized Quality area.

Braveheart Bio develops therapeutics for hypertrophic cardiomyopathy by in-licensing and advancing late-stage drug candidates. Its lead drug, BHB-1893, is a selective small-molecule cardiac myosin inhibitor licensed from Hengrui Pharma for ex-China rights in a deal worth up to $1.1 billion, aimed at improving heart function by tempering myosin activity in HCM. The program includes Phase 2 trials in obstructive and non-obstructive HCM and a Phase 3 trial in China, with global late-stage development planned to begin in 2026. The company differentiates itself by pursuing a best-in-class profile with better efficacy, safety, and dosing, supported by a strong leadership team and high-profile investors, with the goal of delivering an approved therapy that provides meaningful clinical benefit and broader global access.

Company Size

11-50

Company Stage

IPO

Headquarters

San Francisco, California

Founded

2025

Get referred to Braveheart Bio

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • September 2026: LIONHEART-HCM sites are activating, and Braveheart expects first dosing this year.
  • May 2026 nHCM data supported NOBLEHEART-HCM, with U.S. IND open and Phase 3 planned.
  • Camzyos and aficamten validate cardiac myosin inhibition, expanding physician familiarity before Braveheart launches.

What critics are saying

  • Bristol Myers Squibb's Camzyos and Cytokinetics' aficamten already occupy the HCM market.
  • Braveheart owns one asset; a 2027 Phase 3 miss would wipe out its pipeline.
  • The Hengrui license concentrates supply and IP dependence outside China, risking leverage in setbacks.

What makes Braveheart Bio unique

  • BHB-1893’s March 2026 Phase 2 showed rapid LVOT gradient reductions with minimal LVEF change.
  • Braveheart’s August 2026 IPO raised $439.9 million, funding Phase 3 through 2027.
  • Travis Murdoch and Chris Viehbacher bring Biogen-era execution credibility from HI-Bio and Biogen.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

-7%

1 year growth

0%

2 year growth

0%
Minichart
Sep 9th, 2026
Braveheart Bio raises $122.8M in IPO to advance hypertrophic cardiomyopathy drug candidate

Braveheart Bio completed its initial public offering on 7 August 2026, raising $122.8 million in gross proceeds. The biotech company is developing BHB-1893, a drug candidate for treating hypertrophic cardiomyopathy. The IPO significantly strengthened Braveheart Bio's balance sheet. As of 30 June 2026, the company held cash and cash equivalents of $122.8 million, up from $89.2 million at the end of 2025. The company reported a net loss of $18.6 million for the three months ended 30 June 2026, and $32.9 million for the six-month period. Research and development expenses totalled $11.1 million in the second quarter. Braveheart Bio's accumulated deficit stood at $95.9 million as of 30 June 2026. The company has a limited operating history and one product candidate in clinical trials.

GlobeNewswire
Sep 1st, 2026
Braveheart Bio to participate in Cantor Global Healthcare Conference.

Braveheart Bio to participate in Cantor Global Healthcare Conference. SAN FRANCISCO, Sept. 01, 2026 (GLOBE NEWSWIRE) - Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, today announced that it will participate in the Cantor Global Healthcare Conference, being held September 9-11 in New York, NY. Management will participate in a fireside chat on Thursday, September 10, 2026 at 3:20 p.m. EDT. Interested parties may access a live webcast by visiting the News & Events section of the Braveheart website at https://ir.braveheart.bio/, with replays available in a temporary archive following the event. About Braveheart Bio Braveheart Bio is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Braveheart Bio's lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor (CMI) being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Braveheart Bio is aiming to address the limitations of currently available CMIs by designing BHB-1893 for rapid onset, consistent depth of response, preservation of systolic function, prompt reversibility, and a straightforward approach to titration and monitoring. Investor Relations Contact Alexander Sharif New Street Investor Relations [email protected]

Endpoints News
Aug 6th, 2026
Braveheart lands $383M IPO to take Hengrui cardio drug into Phase 3.

Braveheart lands $383M IPO to take Hengrui cardio drug into Phase 3. Biotech correspondent. For the second time this year, a US biotech born out of the pipeline of China-based Hengrui Pharmaceuticals is going public on the Nasdaq. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

MarketScreener
Aug 6th, 2026
Braveheart Bio prices upsized $382.5M IPO for heart disease therapies

Braveheart Bio, a clinical-stage biopharmaceutical company developing therapeutics for hypertrophic cardiomyopathy and other cardiovascular diseases, has priced its upsized initial public offering at $18.00 per share. The San Francisco-based company is offering 21,250,000 shares, with expected gross proceeds of $382.5 million before deducting underwriting discounts and commissions. The shares are expected to begin trading on the Nasdaq Global Market on 6 August 2026 under the ticker symbol "BRVE". The offering is scheduled to close on 7 August 2026, subject to customary closing conditions. Braveheart Bio has granted underwriters a 30-day option to purchase up to an additional 3,187,500 shares. Goldman Sachs, Jefferies, TD Cowen, Stifel, and Cantor are serving as joint book-running managers.

PR Newswire
Mar 26th, 2026
Braveheart Bio appoints Emil deGoma as CMO ahead of 2026 pivotal trial for BHB-1893

Braveheart Bio has appointed Emil deGoma, M.D., as Chief Medical Officer to lead clinical strategy and medical affairs as the company advances BHB-1893 towards a planned global pivotal trial in obstructive hypertrophic cardiomyopathy in 2026. DeGoma joins from Tourmaline Bio, where he served as Senior Vice President of Medical Research. He previously held leadership positions at Akebia Therapeutics, overseeing cardiovascular outcomes trials with over 7,000 patients, and at ChemoCentryx and Penn Medicine. He completed his cardiovascular medicine fellowship at Stanford University and is a Fellow of the American College of Cardiology. Braveheart Bio is a clinical-stage biotechnology company backed by investors including Andreessen Horowitz, Forbion, OrbiMed, Enavate Sciences and Frazier Life Sciences.